Analysts forecast that Haemonetics Co. (NYSE:HAE) will announce $219.52 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Haemonetics’ earnings, with the lowest sales estimate coming in at $216.20 million and the highest estimate coming in at $221.62 million. Haemonetics posted sales of $210.95 million during the same quarter last year, which would indicate a positive year over year growth rate of 4.1%. The business is scheduled to issue its next quarterly earnings report on Monday, August 6th.
According to Zacks, analysts expect that Haemonetics will report full year sales of $946.65 million for the current fiscal year, with estimates ranging from $942.90 million to $952.90 million. For the next year, analysts forecast that the company will post sales of $1.02 billion per share, with estimates ranging from $992.40 million to $1.06 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Haemonetics.
Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.43. The firm had revenue of $233.55 million for the quarter, compared to the consensus estimate of $226.63 million. Haemonetics had a net margin of 5.04% and a return on equity of 12.71%. The business’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.39 earnings per share.
In other Haemonetics news, VP Dan Goldstein sold 518 shares of the stock in a transaction that occurred on Friday, April 6th. The shares were sold at an average price of $54.65, for a total value of $28,308.70. Following the transaction, the vice president now directly owns 4,002 shares in the company, valued at $218,709.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Simon sold 3,595 shares of the stock in a transaction that occurred on Friday, June 29th. The stock was sold at an average price of $40.39, for a total transaction of $145,202.05. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,403 shares of company stock worth $879,703. 1.04% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HAE. Teacher Retirement System of Texas bought a new position in Haemonetics in the fourth quarter worth approximately $1,057,000. Swiss National Bank raised its position in Haemonetics by 2.4% in the fourth quarter. Swiss National Bank now owns 89,600 shares of the medical instruments supplier’s stock worth $5,204,000 after acquiring an additional 2,100 shares during the period. The Manufacturers Life Insurance Company raised its position in Haemonetics by 2.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 40,317 shares of the medical instruments supplier’s stock worth $2,342,000 after acquiring an additional 827 shares during the period. First Allied Advisory Services Inc. bought a new position in Haemonetics in the fourth quarter worth approximately $220,000. Finally, Arizona State Retirement System raised its position in Haemonetics by 225.2% in the fourth quarter. Arizona State Retirement System now owns 88,775 shares of the medical instruments supplier’s stock worth $5,156,000 after acquiring an additional 61,478 shares during the period. Institutional investors and hedge funds own 99.31% of the company’s stock.
Shares of NYSE HAE traded down $0.49 during midday trading on Wednesday, hitting $93.04. The stock had a trading volume of 1,222,989 shares, compared to its average volume of 1,017,153. The company has a market cap of $4.88 billion, a PE ratio of 49.75, a P/E/G ratio of 4.23 and a beta of 0.93. Haemonetics has a 52 week low of $38.47 and a 52 week high of $96.84. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.94 and a current ratio of 1.35.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.